AACR

KRAS mutations represent the most commonly encountered driver oncogene, implicated in approximately 25% of all human cancers, with KRASG12D emerging as a predominant isoform, particularly prevalent in pancreatic, colorectal, and non-small cell lung cancers. Despite its frequency, targeting KRASG12D poses distinct c...

The upcoming AACR 2023 Annual Meeting will have a range of abstracts, including regular abstracts, clinical trials, and late-breaking abstracts. Among the abstracts being presented at the conference, we have listed a few potential abstracts, which we have listed in the below table. The table includes information ab...

Post Lumakras ‘approval,  Adagrasib’s PDUFA date, Novartis now ready to enter the KRASG12C space Novartis is now heading towards its unique KRASG12C inhibitor in patients with advanced non-small cell lung cancer (NSCLC). The company presented the promising preliminary data (Phase Ib) from the KontRASt-01 study e...

TIGIT (T cell immunoreceptor with Ig and ITIM domains) - The red hot corner of immune-oncology market drawing huge Interest Interest in TIGIT has increased since last 2-3 years and several key players are now active in this field including BeiGene’s Ociperlimab, which is in Phase III stage of development fo...